Axsome released their second quarter financial results on Monday August 7th. Just a few highlights from the just completed impressive quarter, are below.
- Auvelity for MDD sales totaled $27.6 million for the quarter
- Sunosi for narcolepsy sales totaled $19.1 million for the quarter
- $468 million in cash on hand, end of quarter
- AXS-12 clinical trial for cataplexy, to read out in the fourth quarter, 2023
- AXS-05 clinical trial for Alzheimer's Disease Agitation, complete first half of 2024
Below are weekly prescriptions of Auvelity for MDD. Thank you for reading.
No comments:
Post a Comment